Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Sarcoma 3Glioblastoma 3Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Ichthyosis, X-Linked 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 100Radiotherapy 49Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 22Bevacizumab 22Lomustine 16Nivolumab 14Surgical Procedures, Operative 10atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioblastoma × ADI PEG20 × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT07389278 2026-02-05

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

University of California, San Francisco

Phase 1/2 Not yet recruiting
97 enrolled
CNS

Glioblastoma, Glioma

NCT04587830 2025-08-26

GBM

Polaris Group

Phase 2 Active not recruiting
100 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡